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such as heart failure and renal dysfunction. The popu­
lation of elderly people is generally increasing and 
these cardiovascular disorders greatly impairs the 
activity and life prognosis of elderly subjects. There­
fore, it is obviously important to control the blood 
pressure in optimal range and prevent the occurrence 
of cardiovascular organ damages, considering that 
hypertension is the most prevalent lifestyle-related 
disease.
Among the classes of antihypertensive drugs, angio­
tensin II receptor blockers（ARB）are widely used 
because ARB rarely cause adverse side effects and 
the inhibition of renin-angiotensin-aldosterone（RAA）
INTRODUCTION
The progression of arteriosclerosis is facilitated by 
high blood pressure, which increases the incidence of 
cardiovascular diseases such as stroke and coronary 
heart disease. Hypertension is also a major risk factor 
for the development of cardiovascular organ damages 
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SUMMARY
We compared treatment with a high-dose angiotensin II receptor blocker（ARB）and combination of 
ARB with a thiazide diuretic in 17 patients with hypertension. A randomized crossover study was per­
formed giving 80 mg telmisartan or fixed-dose combination of 40 mg telmisartan and 12.5 mg hydrochloro­
thiazide for 16 weeks each. Although the clinic blood pressure was comparable between the high-dose 
ARB period（134/81 mmHg）and the combination period（134/82 mmHg）, the morning home blood pres­
sure was lower in the combination period than in the high-dose ARB period（138/82 vs. 151/88 mmHg, p
＝0.026/0.013）. No significant difference was observed in urinary albumin excretion, but estimated glomer­
ular filtration rate was lower in the combination than in the high-dose ARB period（58.9 vs. 62.1 mL/
min/1.73 m2, p＝0.039）. Serum uric acid was higher in the combination than in the high-dose ARB period
（6.7 vs. 5.9 mg/dL p＝0.022）. The indices of glucose metabolism, serum lipids, oxidative stress, inflamma­
tion and adipocytokine did not significantly differ between the two periods. There was no significant differ­
ence in the measurement of endothelium-dependent vasodilation between the two periods. It is suggested 
that the addition of thiazide diuretic to medium-dose ARB is more effective in lengthening the hypotensive 
effect than high-dose ARB, however, care should be taken for the elevation of serum uric acid and the 
decrease in renal function.
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system is supposedly protective against the develop­
ment of cardiovascular tissue and organ injuries 1,2）. 
However, the hypotensive effects of renin-angiotensin 
system inhibitors（RASI）such as angiotensin-convert­
ing enzyme（ACE）inhibitors and ARB depend on the 
intrinsic activity of RAA system to a greater or lesser 
extent, and the usual dose of ARB alone often fails to 
achieve the desired blood pressure level. The next 
step to further lower blood pressure is to increase the 
dose of ARB or to add another class of antihyperten­
sive drug. The protective effects on the cardiovascular 
system are expectedly enhanced by high-dose RASI 
and the addition of diuretics is expected to synergisti­
cally enhance the hypotensive effects of RASI 3〜5）.
In the present study, the therapeutic effects of 
high-dose ARB, 80 mg telmisartan, and fixed dose 
combination of 40 mg telmisartan with a diuretic, 
12.5 mg hydrochlorothiazide are compared in patients 
with essential hypertension.
METHODS
The subjects enrolled in this study were 17 hyper­
tensive patients being treated with medium-dose 
ARB（losartan 50 mg, candesartan 8 mg, valsartan 
80 mg, telmisartan 40 mg, olmesartan 20 mg, irbesar­
tan 100 mg）and the systolic blood pressure（SBP）
and/or the diastolic blood pressure（DBP）did not 
reach the target levels；＜130/80 mmHg for two dia­
betic patients, four patients with chronic glomerulone­
phritis showing proteinuria, and＜140/90 mmHg for 
the other 11 patients. Patients whose serum creatinine 
was 2.0 mg/dL or higher were not included because 
thiazide diuretics are contraindicated. We also exclud­
ed patients with severe hypertension exceeding 
180/110 mmHg or secondary causes of hypertension 
other than stage 1-3 chronic kidney disease. The 
background characteristics of study subjects are 
shown in Table 1. Six patients were concomitantly 
given calcium channel blockers（CCB）and two diabet­
ic patients were given antidiabetic drugs such as bigu­
anides（n＝2）and a-glucosidase inhibitors（n＝1）. In 
addition, lipid-lowering drugs（statins）and antihyper­
uricemic drugs（allopurinaol）were given for six and 
four patients, respectively. The doses of these drugs 
were unchanged throughout the study periods.
The patients were given 80 mg（high dose）telmis­
artan or a fixed-dose combination product of 40 mg
（medium dose）telmisartan and 12.5 mg hydrochloro­
thiazide once daily after breakfast for 16 weeks each, 
according to a randomized crossover design. The 
sequence of treatment periods with high-dose ARB 
and combination therapy was randomized. Office 
blood pressure was measured with a sphygmomanom­
eter in the sitting position after resting for at least 
20 min at each visit every 4 weeks. Home blood pres­
sure was measured consecutively for 7 days before 
each visit using an arm-cuff oscillometric automatic 
manometer within 1 hour of awakening（before drug 
administration）as morning blood pressure and before 
going to bed as evening blood pressure, and the mean 
values were obtained. The type of manometer was 
not specified if an arm-cuff was equipped. Home blood 
pressure values were recorded to a notebook by the 
patient and the data were collected at each visit.
After overnight fasting blood samples were collect­
ed at rest in the sitting position for more than 20 min­
utes on the final day of each treatment period. In 
addition to the routine blood chemistry and blood cell 
counts, plasma high-sensitivity C-reactive protein
（HSCRP）, a marker of inflammation, was measured 
by a highly sensitive sandwich ELISA. The plasma 
levels of malondialdehyde-modified low-density lipo­
protein（MDA-LDL）, a marker of oxidative stress, 
and total adiponectin were also measured by respec­
tive ELISA system. The estimated glomerular filtra­
Table 1　Baseline characteristics of the study subjects
Age, years 65.4±10.1
Gender, male/female 6/11
Body mass index, kg/m2 　26.4±4.8 　
Systolic blood pressure, mmHg 　146.1±7.6  　
Diastolic blood pressure, mmHg 　88.1±8.2 　
Heart rate, bpm 69.6±10.0
Duration of hypertension, years 　19.4±8.3 　
Smoking, ＋/past/− 4/4/9
Habitual alcohol intake, ＋/− 7/10
Complications
　Chronic glomerulonephritis 4
　Diabetes mellitus 2
　Dyslipidemia 7
　Hyperuricemia 4
　Cardiovascular disease 1
Data are the mean±SD.
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tion rate（eGFR）was calculated from the serum creat­
inine level and age by the following equation 6）：eGFR
＝194×Age−0.287×sCr−1.094（×0 .739 for females）. 
Casual urine samples were collected on the final day 
of each treatment period. Urinary albumin was mea­
sured by an immunoturbidimetric method and cor­
rected using the urinary creatinine level.
Reactive hyperemia index（RHI）, an index of endo­
thelial function, and augmentation index（AI）, an 
index of arterial stiffness, were measured using the 
EndoPAT 2000 device（Itamar Medical, Israel）7,8）. 
Measurements were performed by the manufacturer’s 
instruction. Briefly, after longer than 15 minutes of 
supine rest in a quiet and temperature-controlled
（21-24℃）room, beat-to-beat plethysmographic arte­
rial pulse wave amplitude of the middle finger of both 
hands were simultaneously recorded using inflatable 
latex air cuffs. The measurement protocol consists of 
3 consecutive recordings of 5 minutes each. After a 
5 minutes of baseline recording, the blood pressure 
cuff on one arm was inflated to 60 mmHg above the 
baseline systolic blood pressure for 5 minutes. Then, 
the arm cuff was deflated and another 5-minute 
recording was performed. RHI and AI were calculated 
using a computerized automated algorithm. RHI is the 
difference between the post-occlusion and pre-occlu­
sion amplitude on the arm with occlusion divided by 
the same measurement on the control arm.
The study protocol was in accordance with the rec­
ommendations of the World Medical Association for 
biomedical research involving human subjects and 
was approved by the institutional review board. 
Informed consent was obtained from all subjects after 
explaining the study objective and design.
Clinical data were expressed as means±standard 
deviations（SD）. Values between the 2 periods were 
compared by paired t-test, however, Wilcoxon signed-
rank test was applied for the data with skewed distri­
bution. A P value of less than 0.05 was considered to 
be statistically significant.
RESULTS
All the 17 patients showed good adherence to the 
therapy and fulfilled the whole study periods. Table 2 
shows the office blood pressure and heart rate at the 
ends of high-dose ARB and fixed-dose combination 
therapy periods. Body weight was significantly lower 
in the high-dose ARB period than in the combination 
period. There were no significant differences in the 
office SBP, DBP or heart rate between the two treat­
ment periods. However, as shown in Table 3, home 
SBP and DBP in the morning and evening were sig­
nificantly lower in the combination therapy period 
than in the high-dose ARB period, while the heart 
rate did not significantly differ between the two peri­
ods.
Table 4 shows the data of routine blood cell counts 
and blood chemistry at the end of each treatment 
period. The blood hemoglobin concentration and 
hematocrit were slightly but significantly lower in the 
combination period than in the high-dose ARB period. 
Among the blood chemistry data, the serum levels of 
creatinine and uric acid were significantly higher in 
the combination period than in the high-dose ARB 
period. As for the serum electrolytes, serum sodium 
was significantly lower in the combination period than 
in the high-dose ARB period, although the serum 
potassium levels were not significantly different 
between the two periods. Blood glucose, serum insulin 
and serum lipids were shown in Table 5 . These 
parameters of glucose and lipid metabolisms were not 
significantly different between the two treatment peri­
Table 2　 Office blood pressure, heart rate and body weight at the ends of high-dose 
ARB and fixed-dose combination therapy periods.
Variable High-dose ARB Combination P value
SBP, mmHg 　134.2±10.9 　 　133.9±13.5 　 0.927
DBP, mmHg 　81.0±8.8 　 　82.2±9.3 　 0.529
Heart rate, bpm 71.3±10.6 70.6±10.7 0.662
Body weight, kg 64.7±12.4 64.1±12.3 0.033
Data are the mean±SD. ARB：angiotensin II receptor blocker, SBP：systolic blood 
pressure, DBP：diastolic blood pressure.
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Table 3　 Averaged home blood pressure and heart rate in the last weeks of high-
dose ARB and fixed-dose combination therapy periods.
Variable High-dose ARB Combination P value
Morning
　SBP, mmHg 　151.2±19.9 　 　138.7±14.5 　 0.026
　DBP, mmHg 88.5±11.2 　82.6±6.4 　 0.013
　Heart rate, bpm 70.6±11.7 70.2±11.0 0.789
Evening
　SBP, mmHg 　141.9±19.2 　 　131.8±14.6 　 0.043
　DBP, mmHg 82.8±14.0 76.9±76.0 0.017
　Heart rate, bpm 　71.4±8.5 　 71.7±10.5 0.863
Data are the mean±SD. ARB：angiotensin II receptor blocker, SBP：systolic blood 
pressure, DBP：diastolic blood pressure.
Table 4　 Laboratory data at the ends of high-dose ARB and fixed-dose combination therapy periods.
Variable High-dose ARB Combination P value
White blood cell, x10 3/mm3 6.46±2.15 6.12±1.66 0.174
Red blood cells, x10 6/mm3 4.50±0.34 4.54±0.44 0.028
Blood hemoglobin, g/dL 　13.9±1.0 　 　14.0±1.4 　 0.035
Hematocrit, ％ 　41.5±2.6 　 　41.9±4.1 　 0.015
Platelet, x10 3/mm3 　21.5±6.7 　 　51.4±5.6 　 0.709
Serum
　Aspartate transaminase, U/L 　15.8±7.7 　 18.1±12.7 0.146
　Alanine transaminase, U/L 18.2±16.4 17.6±16.5 0.758
　Total protein, g/dL 7.1±0.3 7.2±0.3 0.096
　Albumin, g/dL 4.0±0.3 4.0±0.3 0.670
　Na, mEq/L 　141.1±2.2  　 　140.2±1.7  　 0.025
　K, mEq/L 4.3±0.3 4.2±0.3 0.720
　Urea nitrogen, mg/dL 　16.5±4.1 　 　17.6±6.2 　 0.245
　Creatinine, mg/dL 0.86±0.24 0.91±0.27 0.040
　Uric acid, mg/dL 5.9±0.8 6.7±1.4 0.022
Data are the mean±SD. ARB：angiotensin II receptor blocker.
Table 5　 Indices of glucose metabolism and serum lipids at the ends of high-dose ARB and 
fixed-dose combination therapy periods.
Variable High-dose ARB Combination P value
Blood gluocose, mg/dL 　106±17 　 　107±21 　 0.753
Hemoglobin A1c, ％ 5.7±0.8 5.9±0.9 0.147
Serum
　Insulin, mU/L 14.4±11.1 12.9±12.4 0.410
　HDL-cholesterol, mg/dL 56±12 56±14 0.948
　LDL-cholesterol, mg/dL 　125±36 　 　129±39 　 0.591
　Triglycerides, mg/dL 　139±73 　 　136±90 　 0.876
Data are the mean±SD. ARB：angiotensin II receptor blocker, HDL：high-density lipoprotein, 
LDL：low-density lipoprotein.
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dependent vasodilation, and AI, an index of arterial 
stiffness, measured at the end of each treatment peri­
od. Either the values of RHI or AI were not signifi­
cantly different between the two periods.
DISCUSSION
The blood pressure level of 140/90 mmHg or higher 
is generally recognized as hypertension and the latest 
versions of guidelines for the management of hyper­
tension recommend the target blood pressure lower 
than this 9〜11）. However, there is not an apparent 
threshold level from which higher blood pressure is 
associated with the increase in cardiovascular diseas­
es. Meta-analysis of prospective observational studies 
have indicated that there is a linear relationship 
between blood pressure and the risk of cardiovascular 
diseases such as stroke and myocardial infarction 12）. 
ods.
The left panel of Figure 1 shows plasma HSCRP 
and the middle panel shows plasma MDA-HDL. 
These markers of inflammation and oxidative stress 
did not significantly differ between the high-dose 
ARB and the combination periods. Regarding adipo­
nectin, a beneficial cytokine produced by adipocytes, 
the plasma levels were not significantly different 
between the two periods as shown in the right panel 
of Figure 1.
The eGFR and the urinary albumin excretion of the 
study subjects at the end of each treatment period 
were depicted in Figure 2. While the eGFR slightly 
reduced during the combination period, the urinary 
albumin excretion did not significantly differ in the 
high-dose ARB and the combination periods.
Figure 3 presents RHI, an index of endothelium-
Figure 1　 Plasma levels of high-sensitivity C-reactive protein（HSCRP, left panel）, malondialdehyde-
modified low-density lipoprotein（MDA-LDL, middle panel）, and total adiponectin（right 
panel）at the ends of high-dose ARB and fixed-dose combination therapy periods. Data are 
mean±SD. ARB：angiotensin II receptor blocker.
Figure 2　 Estimated glomerular filtration rate（eGFR, left panel）and urinary albumin 
excretion（right panel）at the ends of high-dose ARB and fixed-dose combination 
therapy periods. Data are mean±SD. ARB：angiotensin II receptor blocker.
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long plasma half-life as compared with other ARB 
clinically used, the duration of hypotensive effect by 
high-dose telmisartan may not be sufficient to cover 
24 hours.
Even if the office blood pressure is controlled in 
normal range, diurnal blood pressure changes such as 
morning surge and the lack of nocturnal dipping are 
known to raise the risk of cardiovascular organ inju­
ries. Inappropriate renal excretion of Na is thought to 
contribute to the non-dipping pattern of blood pres­
sure change, and it has been reported that the addi­
tion of diuretics reduce the necessity to maintain high 
blood pressure level to excrete Na during nighttime 
and change the non-dipper pattern into dipper 14）. 
Thus, the hypotensive effect is expectedly lengthened 
by the combination of RASI and thiazide diuretics.
Among the various components of the RAA system, 
angiotensin II enhances the production of free radi­
cals, promotes cell growth, and increases the synthesis 
of inflammatory and profibrotic cytokines 15,16）. In addi­
tion, it has been revealed that aldosterone also pro­
motes free radical production and endothelial dysfunc­
tion, as well as having mitogenic and profibrotic 
actions 17,18）. These nonhemodynamic effects of angio­
tensin II and aldosterone are deleterious to the cardio­
vascular system and cause inflammation, fibrosis, and 
scarring of various tissues that lead to cardiovascular 
organ injuries and increase the incidence of cardiovas­
cular diseases. Therefore, high-dose RASI are expect­
ed to exhibit protective effects against cardiovascular 
This relationship also exists even in the normal blood 
pressure range below 140/90 mmHg down to 115/75 
mmHg. Moreover, in the recent Systolic Blood Pres­
sure Intervention Trial（SPRINT）, the intensive treat­
ment hypertensive patients with target SBP less than 
120 mmHg showed lower rates of cardiovascular 
events and death than in the standard treatment 
group targeted less than 140 mm Hg13）. Therefore, 
stricter target blood pressure level such as 130/85 
mmHg may be preferable in order to achieve better 
prevention of cardiovascular diseases in hypertensive 
patients. In the real world clinical practice, generally 
half hypertensive patients under antihypertensive 
treatment do not achieve even the target blood pres­
sure level of 140/90 mmHg and intensification of anti­
hypertensive drug therapy such as increasing the 
dose and combination of multiple agents is needed.
In the present study, therapeutic effects of high-
dose ARB and combination therapy with medium-
dosed ARB and thiazide diuretic were compared, and 
office blood pressure was comparably lowered in 
either treatment period, however, the morning and 
evening home blood pressure was better lowered by 
the combination therapy than by the high-dose ARB 
therapy. Out of office blood pressure values obtained 
by ambulatory blood pressure monitoring（ABPM）or 
home blood pressure measurement have been shown 
to yield better prediction than office blood pressure 
for the incidence of target organ damages and cardio­
vascular diseases. Although telmisartan has relatively 
Figure 3　 Comparisons of relative hyperemia index（RHI）and augmentation index（AI）
at the ends of high-dose ARB and fixed-dose combination therapy periods. 
Data are mean±SD. ARB：angiotensin II receptor blocker.
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such as ACE inhibitors and ARB are expected to 
exhibit protective effects against the development vas­
cular injuries by suppressing the actions of angioten­
sin II and aldosterone 1,2）. However, the results of pres­
ent study suggest that clinical significance of such 
vascular effects by telmisartan are not prominent 
although this drug activates PPAR-g  dose-dependent­
ly.
Two drugs or more are often required in order to 
achieve the target blood pressure. The combination of 
RASI and diuretics is thought to be effective in inten­
sifying the hypotensive effects of each other and 
avoiding the occurrence of adverse effects. The RAA 
system enhanced by the natriuretic action of diuretics 
is suppressed by RASI and salt-sensitivity induced by 
RASI is reduced by diuretics. As for the adverse 
effects, diuretics and RASI exert opposite influences 
on the metabolism of K, glucose and lipids thereby 
canceling the demerits of each other. Conformably in 
our study, serum K, lipids and glucose metabolism 
markers were not adversely affected in the combina­
tion period as compared with the high-dose ARB 
period in this study. On the other hand, thiazide 
diuretics increase serum uric acid, while RASI gener­
ally do not affect the serum uric acid level. Among 
ARB, losartan and irbesartan have been shown to 
facilitate uric acid excretion by inhibiting URAT-1, an 
transporter of uric acid reabsorption in the renal 
tubules and reduce serum uric acid 32,33）. In the pres­
ent study, serum uric acid was significantly higher in 
the combination period than in the high-dose ARB 
period. Although telmisartan has been also shown to 
inhibit URAT-1, the lipophilic property may hamper 
its penetration to the apical side of renal tubules and 
inhibition of URAT-1 in vivo.
The protective effects of RASI on cardiovascular 
system are supposed to grow with increasing dose 3,4）. 
Also in the kidney, RASI have shown to reduce pro­
teinuria and albuminuria in a dose-dependent man­
ner 34,35）. In the earlier studies examined the renopro­
tective effects of antihypertensive therapy combined 
RASI with diuretics or CCB, the diuretic combination 
is superior in reducing albuminuria but inferior in pre­
serving eGFR as compared to the CCB combina­
tion 36,37）. In the present study compared high-dose 
ARB and combination of medium-dose ARB with a 
system in addition to their hypotensive effects. Espe­
cially, telmisartan is known to dose-dependently acti­
vate peroxisome proliferator-activated receptor-gam­
ma（PPAR-g）, a transcription factor of nuclear 
hormone receptor, which has actions such as improv­
ing insulin resistance, reducing inflammatory cyto­
kines and increasing adiponectin 19〜21）. Adiponectin 
produced by adipocytes also has beneficial actions 
such as inhibiting inflammatory vascular injuries and 
improving glucose and lipid metabolism 22,23）. On the 
contrary, reduction of body fluid volume by diuretics 
stimulates circulating RAA system factors, such as 
angiotensin II and aldosterone, which could possibly 
have an adverse influence on the development of car­
diovascular organ damage in hypertensive patients, 
although the RAA system in cardiovascular tissues 
may not always show a parallel response to circulat­
ing hormone levels. However, in the present study, 
high-dose telmisartan did not significantly influence 
the glucose metabolism, serum lipids plasma adiponec­
tin and circulating markers of oxidative stress and 
inflammation as compared with medium-dose. There­
fore, the dose-dependent beneficial effects of telmisar­
tan may not be apparent in clinical situations.
It is assumed that atherosclerotic lesions in the 
arterial system are initiated by functional disorder of 
the vascular endothelium. This causes the reduced 
capacity to generate nitric oxide（NO）in response to 
various stimuli resulting in impaired endothelium-
dependent vasorelaxation. On the other hand, AI 
examined in this study reflects functional and struc­
tural stiffening of arterial system and increases with 
the development of arteriosclerosis. The development 
of endothelial dysfunction and arterial stiffening is 
contributed by aging, smoking and lifestyle-related 
diseases such as diabetes, hypertension and dyslipid­
emia. In addition to these classical risk factors of ath­
erosclerosis, novel factors such as inflammation and 
oxidative stress are thought to participate in the etiol­
ogy and pathogenesis of vascular injuries 24〜27）. It is 
recognized that the existence of endothelial dysfunc­
tion and arterial stiffening is predictive of the inci­
dence of cardiovascular events 28〜31）. Therefore, it is 
desirable to consider vascular protection in the treat­
ment of hypertensive patients in order to effectively 
prevent cardiovascular diseases. In this context, RASI 
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thiazide diuretic, serum creatinine was higher result­
ing in lower eGFR in the combination period than in 
the high-dose ARB period, while the urinary albumin 
excretion did not significantly differ between the two 
periods. Thus, when thiazide diuretics are used in 
antihypertensive treatment, it should be kept in mind 
for the reduction of renal function as well as for 
hyperuricemia.
In summary, we compared the therapeutic effects of 
antihypertensive therapies with high-dose ARB and 
the fixed-dose combination of medium-dose ARB with 
a thiazide diuretic in hypertensive patients showing 
poor blood pressure control by medium-dose ARB. It 
is suggested that the combination therapy is superior 
to the high-dose ARB in controlling blood pressure 
over 24 hours, however, care should be taken for the 
increase in serum uric acid the reduction of renal 
function.
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